Phases précoces tumeurs solides
DRIIV-1 (OX2016 -203-01)
An open-label, dose-escalation phase I study to assess the safety, pharmacokinetics and pharmacodynamics of AsiDNA, a DNA repair inhibitor administered intravenously in patients with advanced solid tumors.
Paris
CHRISTOPHE LE TOURNEAU